EGFR and non-small cell lung carcinoma: In the Chinese setting, gene-guided gefitinib maintenance treatment for patients with advanced NSCLC and EGFR mutation-positive tumors after first-line chemotherapy is indicated as a cost-effective chemotherapy option compared to routine follow-up based on its superior PFS benefit and the use of the Patient Assistance Program.